Literature DB >> 15538596

Low doses of clozapine may stabilize treatment-resistant bipolar patients.

Bettina S Fehr1, M Erkan Ozcan, Trisha Suppes.   

Abstract

Open, uncontrolled studies suggest clozapine can have mood-stabilizing effects in treatment-resistant bipolar disorder. Unfortunately, the side effect profile limits clozapine's use at high doses. We report a series of nine bipolar I disorder patients who improved on relatively low doses of clozapine add-on therapy (250 mg or lower). Retrospectively abstracted clinical data identified nine patients with bipolar I disorder, as defined by DSMIV criteria, treated with low-dose clozapine at inpatient and outpatient settings. Monthly symptom evaluations were collected prospectively using standard assessments. Symptoms of mania and mood lability improved in all patients. Three patients demonstrated striking mood stabilization and returned to previous levels of functioning; five patients evidenced moderate improvement in mood stabilization and functioning; and one patient showed a minimal response. Overall, clozapine did not have a significant antidepressant effect. The mean clozapine dose at the end of the study was 156.3 +/- 77.6 mg/day, and duration of treatment was 12 months. Residual side effects were mild. The symptomatic improvement in these prospectively evaluated patients is consistent with our clinical impression in the majority of patients with bipolar disorder taking clozapine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15538596     DOI: 10.1007/s00406-004-0528-8

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  34 in total

1.  Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study.

Authors:  A F Oberholzer; C Hendriksen; A U Monsch; B Heierli; H B Stähelin
Journal:  Int Psychogeriatr       Date:  1992       Impact factor: 3.878

2.  Development of transient obsessive-compulsive symptoms during treatment with clozapine.

Authors:  V J Patil
Journal:  Am J Psychiatry       Date:  1992-02       Impact factor: 18.112

Review 3.  Use of atypical antipsychotics in mood disorders.

Authors:  R Weizman; A Weizman
Journal:  Curr Opin Investig Drugs       Date:  2001-07

4.  Atypical antipsychotics in bipolar and schizoaffective disorders.

Authors:  E S Brown; N R Thomas; T Carmody; S Mahadi; V A Nejtek
Journal:  Pharmacopsychiatry       Date:  2001-03       Impact factor: 5.788

5.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

6.  Recurrence of bipolar disorders and major depression. A life-long perspective.

Authors:  Jules Angst; Alex Gamma; Robert Sellaro; Philip W Lavori; Heping Zhang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2003-10       Impact factor: 5.270

7.  Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease.

Authors:  J M Rabey; T A Treves; M Y Neufeld; E Orlov; A D Korczyn
Journal:  Neurology       Date:  1995-03       Impact factor: 9.910

8.  The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale.

Authors:  P Bech; T G Bolwig; P Kramp; O J Rafaelsen
Journal:  Acta Psychiatr Scand       Date:  1979-04       Impact factor: 6.392

9.  Clozapine for treatment-refractory mania.

Authors:  J R Calabrese; S E Kimmel; M J Woyshville; D J Rapport; C J Faust; P A Thompson; H Y Meltzer
Journal:  Am J Psychiatry       Date:  1996-06       Impact factor: 18.112

10.  Is clozapine a mood stabilizer?

Authors:  C A Zarate; M Tohen; M D Banov; M K Weiss; J O Cole
Journal:  J Clin Psychiatry       Date:  1995-03       Impact factor: 4.384

View more
  1 in total

1.  Integrative Genomic-Epigenomic Analysis of Clozapine-Treated Patients with Refractory Psychosis.

Authors:  Yerye Gibrán Mayén-Lobo; José Jaime Martínez-Magaña; Blanca Estela Pérez-Aldana; Alberto Ortega-Vázquez; Alma Delia Genis-Mendoza; David José Dávila-Ortiz de Montellano; Ernesto Soto-Reyes; Humberto Nicolini; Marisol López-López; Nancy Monroy-Jaramillo
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.